journal article·2026-01

Lattice‐distortion Induced Niobium‐based Perovskite Polarization Cascade Regulates Na + /K + ATPase to Enhance Pyroptosis for Cancer Treatment

Kexin Zhang, Dong Li, Kaiyang Wang, Bingbing Duan, Lichao Zhu, Renmiao Peng, Wenjing Lv, Shunye Zhang, Yiting Ma, Guanwei Cheng, Xijian Liu, Lingxiao Zhang, Jiarui Wang, Xiaofeng Zhu, Lile Dong, Yu Luo

Advanced Functional Materials· Volume 36· Issue 1
Publisher page

Abstract

Abstract Designing lattice‐distortion‐induced perovskite materials to disrupt intracellular soNa + homeostasis via targeting sodium–potassium ATPase (Na + /K + ATPase) has emerged as a promising therapeutic strategy in cancer treatment. However, precise manipulation of Na + balance to achieve targeted anti‐tumor effects remains challenging. Here, a lattice‐distorted and oxygen vacancy‐rich niobium‐based perovskite, NaNbO 3 (NNO x ), is synthesized by utilizing the piezo‐catalytic and photothermal properties of NNO x , and a cascade regulation of Na + /K + ATPase is achieved. Particularly, under ultrasound and near‐infrared II laser irradiation, NNO x not only releases exogenous Na + to elevate local intracellular Na + concentrations but also efficiently generates reactive oxygen species, inducing mitochondrial damage and impairing ATP synthesis in tumor cells. This mitochondrial dysfunction dramatically reduces Na + /K + ATPase activity, impairs cellular Na + efflux, and further exacerbates intracellular Na + accumulation. Consequently, the severe ionic imbalance leads to rapid osmotic swelling and bubble formation, triggering pyroptotic cell death and robust anti‐tumor immune responses. In vitro and in vivo studies demonstrate that NNO x efficiently suppresses tumor growth and activates potent anti‐tumor immunity, highlighting an innovative strategy for ionic disruption‐induced pyroptosis and immunogenic cell death. This approach provides valuable insights for future ionic homeostasis‐targeted cancer immunotherapy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Perovskite Materials and Applications · MXene and MAX Phase Materials · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Shanghai Engineering Research Center of Pharmaceutical Intelligent Equipment Shanghai Frontiers Science Research Center for Druggability of Cardiovascular Non‐coding RNA Institute for Frontier Medical Technology School of Chemistry and Chemical Engineering Shanghai University of Engineering Science Shanghai 201620 P. R. China

Interdisciplinary Nanoscience Center (INANO) Aarhus University Aarhus 8000 Denmark

Ganjiang Innovation Academy Chinese Academy of Sciences Ganzhou 341000 P. R. China

Funding

National Natural Science Foundation of China · Ganjiang Innovation Academy, Chinese Academy of Sciences

References (46)

Show source-provided references
1. 10.1007/s00210-024-03031-910.1007/s00210-024-03031-9 ↗
2. 10.1038/s41591-024-03486-610.1038/s41591-024-03486-6 ↗
3. 10.1242/bio.06026910.1242/bio.060269 ↗
4. 10.1021/jacs.4c0510310.1021/jacs.4c05103 ↗
5. 10.1038/s41467-023-40954-y10.1038/s41467-023-40954-y ↗
6. 10.1038/s41566-024-01387-110.1038/s41566-024-01387-1 ↗
7. Zhang M. · Adv. Funct. Mater. · 2023 · 33
8. 10.1002/ange.20241986710.1002/ange.202419867 ↗
9. 10.1002/anie.20241038110.1002/anie.202410381 ↗
10. 10.1002/adma.20230064810.1002/adma.202300648 ↗
11. 10.1021/jacs.4c1480410.1021/jacs.4c14804 ↗
12. 10.1002/adfm.20240875410.1002/adfm.202408754 ↗
13. 10.1016/j.nanoen.2024.10973810.1016/j.nanoen.2024.109738 ↗
14. 10.1016/j.nantod.2025.10278510.1016/j.nantod.2025.102785 ↗
15. 10.1021/jacs.2c0960810.1021/jacs.2c09608 ↗
16. 10.1016/j.fmre.2022.04.02110.1016/j.fmre.2022.04.021 ↗
17. 10.1021/jacs.4c0956610.1021/jacs.4c09566 ↗
18. 10.1002/adma.20240125210.1002/adma.202401252 ↗
19. Sun S. · ACS Nano · 2024 · 18
20. 10.1038/s41467-023-42509-710.1038/s41467-023-42509-7 ↗
21. 10.1016/j.fmre.2021.10.00710.1016/j.fmre.2021.10.007 ↗
22. 10.1038/s41590-024-01918-610.1038/s41590-024-01918-6 ↗
23. 10.1038/s41416-022-01802-w10.1038/s41416-022-01802-w ↗
24. 10.1038/s42003-023-04946-410.1038/s42003-023-04946-4 ↗
25. 10.1002/adfm.20240189710.1002/adfm.202401897 ↗
26. 10.1002/adma.20231142910.1002/adma.202311429 ↗
27. 10.1002/advs.20240259910.1002/advs.202402599 ↗
28. 10.1021/jacs.2c0996710.1021/jacs.2c09967 ↗
29. 10.1038/s41571-020-0410-210.1038/s41571-020-0410-2 ↗
30. 10.1038/s41467-022-30306-710.1038/s41467-022-30306-7 ↗
31. 10.1038/s41467-024-52535-810.1038/s41467-024-52535-8 ↗
32. 10.1002/adfm.20241298310.1002/adfm.202412983 ↗
33. 10.1021/acs.nanolett.4c0202710.1021/acs.nanolett.4c02027 ↗
34. 10.1002/adfm.20240715310.1002/adfm.202407153 ↗
35. 10.1002/adma.20241742210.1002/adma.202417422 ↗
36. 10.1002/adfm.20242015810.1002/adfm.202420158 ↗
37. 10.1002/adma.20221226710.1002/adma.202212267 ↗
38. 10.1021/acsnano.3c0476710.1021/acsnano.3c04767 ↗
39. 10.1002/adma.20230296110.1002/adma.202302961 ↗
40. 10.1002/ange.20242250210.1002/ange.202422502 ↗
41. 10.1002/adfm.20240933510.1002/adfm.202409335 ↗
42. 10.1002/adfm.20242329110.1002/adfm.202423291 ↗
43. 10.1021/jacs.5c0084310.1021/jacs.5c00843 ↗
44. 10.1002/adfm.20240592910.1002/adfm.202405929 ↗
45. 10.1002/adfm.20240416910.1002/adfm.202404169 ↗
46. 10.1002/adma.20240906610.1002/adma.202409066 ↗